Replimune's RP1 Faces Second FDA Verdict: What April 10 Means for Biotech CFD Traders

Event Summary

Replimune Group Inc. (NASDAQ: REPL) received a Complete Response Letter (CRL) from the FDA on July 22, 2025, rejecting its Biologics License Application for RP1 — an oncolytic herpes simplex virus — in combination with Bristol Myers Squibb's nivolumab (Opdivo) for anti-PD-1 refractory advanced melanoma. According to FierceBiotech and STAT News, the FDA cited the single-arm IGNYTE trial (n=140) as insufficient, flagging lack of a well-controlled design and patient population heterogeneity — despite a 33% overall response rate and 33.7-month response duration.

Replimune resubmitted its BLA in October 2025, with the FDA accepting a new PDUFA decision date of April 10, 2026. As reported by BioSpace, this decision is now viewed as a bellwether for FDA direction under new leadership, with observers watching whether CBER under Dr. Vinay Prasad will maintain the stricter evidentiary bar set in July. Peak sales potential for RP1 was estimated at $800M annually by analysts prior to the initial rejection.

Leverage Impact Analysis

The original CRL in July 2025 sent REPL crashing approximately 75–77% — from roughly $12–13 to $3.07 on 1.57M volume, according to Investing.com. This is the archetype of a binary catalyst event that destroys leveraged long positions in biotech CFDs.

On CoinUnited.io, traders can access stock CFDs with up to 2000x leverage and zero trading fees — but binary FDA outcomes demand extreme position-sizing discipline. Consider: a trader holding a 50x long REPL CFD at $12 would have faced a ~$9 adverse move, representing a ~3,750% loss relative to margin — a near-instantaneous liquidation scenario. Even at 10x leverage, margin would have been wiped multiple times over within a single session.

For the April 10, 2026 re-decision, the asymmetry is notable. Cantor Fitzgerald downgraded REPL to Neutral post-CRL, while Barclays maintained Overweight with a $17 price target and BMO holds a $27 target, per Investing.com. This wide analyst divergence signals high implied volatility into the event. Traders on either side should size conservatively — the outcome is binary, not directional. Monitor open interest on CoinUnited.io for positioning signals ahead of the decision date.

Cross-Market Impact

This event is biotech-specific with limited macro spillover to forex, commodities, or crypto. The primary cross-market consideration is sector contagion within biotech. The State Street SPDR S&P Biotech ETF (XBI) and IBB are exposed to FDA policy risk broadly — stricter single-arm trial scrutiny signals potential pipeline delays for oncology peers relying on similar trial designs.

For traders monitoring the broader 2026 Stocks Market Outlook, this case highlights how FDA regulatory posture under new leadership represents a sector-level headwind for small-cap biotech CFDs beyond REPL itself. The Complete Guide to Trading Sectors Across Markets in 2026 provides additional context on navigating event-driven biotech exposure.

No material correlation to DXY, gold, oil, or crypto markets has been identified in the available research.

Trading Considerations

With REPL trading near post-CRL lows (~$3.07 per research data), the risk/reward calculus hinges entirely on the April 10 FDA decision. Analyst price targets of $17–$27 suggest substantial upside if approved, but Replimune's $484M cash position (as of March 31, 2024) may be insufficient to fund a required randomized trial if rejected again, per analyst commentary.

Key levels to watch: the post-CRL low near $3.07 as structural support, and pre-CRL range ($12–$13) as the recovery target on approval. Given the binary nature of the catalyst, traders should avoid holding leveraged CFD positions through the announcement without defined stop parameters.

Trade Avidity Biosciences, Inc. on CoinUnited.io

Trade RNAM with up to 1000xx leverage → | Create Free Account